Verdict No. 3053 · Search date 2026-09-08 · Methodology v1.0
500-mg dried ginger-powder capsules,
does it really help with Reduction of office systolic blood pressure in adults with metabolic syndrome?
30-Second Summary
C
Evidence Grade C · 50 · Safety caution
This verdict is limited to office SBP; DBP, ambulatory pressure, and endothelial function are separate.
Caution. Monitor dizziness, hypotension, and interactions when combined with blood-pressure medicines; do not reduce prescribed therapy without advice.
What the
research showsGrade C with 50 points. In a 37-completer metabolic-syndrome trial, 2 g/day of ginger powder for 12 weeks did not establish an SBP change (adjusted P=.165). Because matching SBP prespecification is unclear, this was not labeled E0; the broader low-certainty 2026 pooled signal remains supportive only.
research showsGrade C with 50 points. In a 37-completer metabolic-syndrome trial, 2 g/day of ginger powder for 12 weeks did not establish an SBP change (adjusted P=.165). Because matching SBP prespecification is unclear, this was not labeled E0; the broader low-certainty 2026 pooled signal remains supportive only.
What the
ads claimThe evidence does not establish antihypertensive replacement, cardiovascular-event prevention, or 2 g/day as an optimal dose.
ads claimThe evidence does not establish antihypertensive replacement, cardiovascular-event prevention, or 2 g/day as an optimal dose.
Useful facts when choosing a product
- This verdict applies only to the exact formulation, route, dose, duration, population, endpoint, and comparator shown above.
- Ginger food, powder, standardized extract, essential oil, topical products, and combination products are not interchangeable.
- Caution. Monitor dizziness, hypotension, and interactions when combined with blood-pressure medicines; do not reduce prescribed therapy without advice.
Chamgap Semantic Classification Code
Permanent code issued
S.ginger.oral.systolic-blood-pressure.reduce.placeboSupplements and nutraceuticals > Ginger > Oral > Systolic blood pressure > Reduction claim > Placebo or control care
Issued for office SBP; DBP and ambulatory blood pressure remain separate. The code identifies the intervention and claim; it never contains the evidence grade, score, or safety result.
Exact Claim Classification
These independent facets prevent evidence from different forms, routes, populations, effects, and comparators from being mixed.
| Intervention class | S · Supplement or nutraceutical |
|---|---|
| Canonical ingredient or intervention | Ginger |
| Source or part used | Rhizome of Zingiber officinale Roscoe |
| Formulation or processing | 500-mg dried ginger-powder capsules; assay units unclear |
| Route | Oral |
| Dose | 2 g/day |
| Duration | Twelve weeks |
| Population | Adults with metabolic syndrome; mean baseline SBP about 121 mmHg; antihypertensive users excluded |
| Effect or condition | Systolic-blood-pressure reduction |
| Primary endpoint | Between-group difference in 12-week office SBP change |
| Comparator | Starch placebo plus the same lifestyle counseling |
| Duplicate-detection key | ginger|500mg-dried-powder-capsules|oral|metabolic-syndrome-adults-no-antihypertensives|office-sbp-reduction|12-weeks |
Gap Measurement · Verdict 3053 · C 50
What the research actually shows
A 2026 GRADE dose-response analysis was compared with a diabetes-only synthesis.
Why this is classified as C (50)
Academic funding is a strength, but SBP prespecification, an adjusted confidence interval, and a clinical threshold are unresolved, with a small completer analysis; the result is C with 50 points.
Counterpoint. A 2026 type-2-diabetes-only synthesis estimated a much smaller systolic difference of -1.62 mmHg.
Rejudgment record. Independent Codex cross-check — One formulation, one route, one population, one claim, one principal endpoint and comparator
Scoring profile behind this grade
| Endpoint | S | Surrogate marker - laboratory or imaging measures |
| Replication | R1 | Single confirmatory trial |
| Independence | I2 | Decisive evidence is publicly or non-profit funded |
| Effect size | EX | The clinical size of the effect could not be judged |
| Precision | CX | No pooled confidence interval could be confirmed |
The scoring table and the verdict agree (C).
Cross-check — AI research and Codex final gate
AI was used for research and drafting. Blind grading, adversarial audit, and the methodology boundary rules were then reapplied before Codex performed the final evidence, grade, copy, and build checks. If a grade cannot be narrowed, both evidence positions and their reasons are published.
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Effects of ginger supplementation on anthropometric, glycemic and metabolic parameters in subjects with metabolic syndrome: A randomized, double-blind, placebo-controlled study | The cited design, allocation, masking, endpoint hierarchy, and analysis limitations were independently checked. | 18 | Funding, product support, employee authorship, and declared conflicts were assessed separately. | The principal endpoint contract is preserved; secondary outcomes remain separate. | Verified estimates are preserved; missing confidence intervals or event counts were not invented. | Evidence weight reflects directness, formulation match, endpoint hierarchy, and reporting limitations. |
| Ginger Supplementation and Blood Pressure in Adults: A GRADE-Based Systematic Review and Dose-Response Meta-Analysis of Randomized Controlled Trials | The cited design, allocation, masking, endpoint hierarchy, and analysis limitations were independently checked. | 13 | Funding, product support, employee authorship, and declared conflicts were assessed separately. | The principal endpoint contract is preserved; secondary outcomes remain separate. | Verified estimates are preserved; missing confidence intervals or event counts were not invented. | Evidence weight reflects directness, formulation match, endpoint hierarchy, and reporting limitations. |
Receipt — 2 References
Of 2 cited sources, 1 had limited original-page access (blocked or summary-only) and were verified via index/summary, marked partial; the rest were verified at the original page. As of 2026-09-08.
Rahimlou M et al. Diabetol Metab Syndr. 2019. PMID: 31275882. PMCID: PMC6582048. DOI: 10.1007/s40200-019-00397-z.
partialKarimi M et al. J Hum Nutr Diet. 2026;39:e70329. PMID: 42566667. PMCID: PMC13450692. DOI: 10.1111/jhn.70329.
checkedResearch and draft: AI used · Cross-check: blind grading and adversarial audit
Final verification and publication gate: Codex · Verification cutoff: 2026-09-08 · Corrections: none
Final verification and publication gate: Codex · Verification cutoff: 2026-09-08 · Corrections: none
Cite this verdict
[Chamgap] Ginger Powder for Systolic Blood Pressure—A Small Metabolic-Syndrome Trial Did Not Establish a Reduction — Evidence Grade C·50. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/heart/oral-ginger-adults-systolic-blood-pressure/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.